A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma-Reference-Cited by-同舟云学术

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

Published:2017-07-19 Issue:399 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

O’Rourke Donald M.¹^ORCID,Nasrallah MacLean P.²^ORCID,Desai Arati³^ORCID,Melenhorst Jan J.⁴^ORCID,Mansfield Keith⁵^ORCID,Morrissette Jennifer J. D.⁶^ORCID,Martinez-Lage Maria²^ORCID,Brem Steven¹^ORCID,Maloney Eileen¹,Shen Angela⁷^ORCID,Isaacs Randi⁵^ORCID,Mohan Suyash⁸,Plesa Gabriela⁴^ORCID,Lacey Simon F.⁴^ORCID,Navenot Jean-Marc⁴^ORCID,Zheng Zhaohui⁴^ORCID,Levine Bruce L.⁴^ORCID,Okada Hideho⁹,June Carl H.⁴^ORCID,Brogdon Jennifer L.⁵,Maus Marcela V.¹⁰^ORCID

Affiliation:

1. Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.

2. Division of Neuropathology, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.

3. Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.

4. Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA 19104, USA.

5. Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.

6. Division of Precision and Computational Diagnostics, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.

7. Novartis Oncology, East Hanover, NJ 07936, USA.

8. Division of Neuroradiology, Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.

9. Department of Neurosurgery, University of California, San Francisco, San Francisco, CA 94143, USA.

10. Cellular Immunotherapy Program, Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, MA 02129, USA.

Abstract

A trial of autologous T cells redirected to a specific mutation in glioblastoma patients illustrates mechanisms of resistance.

Funder

NIH

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference51 articles.

1. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

2. Antiangiogenic strategies for treatment of malignant gliomas

3. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme

4. Targeting multiple kinases in glioblastoma multiforme

5. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma

Cited by 1277 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The potential of mesenchymal stem cell coexpressing cytosine deaminase and secretory IL18-FC chimeric cytokine in suppressing glioblastoma recurrence;International Immunopharmacology;2024-12

2. Regional and intratumoral adoptive T-cell therapy;Immuno-Oncology and Technology;2024-12

3. B cells enhance EphA2 chimeric antigen receptor T cells cytotoxicity against glioblastoma via improving persistence;Human Immunology;2024-11

4. Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies;The Journal of Steroid Biochemistry and Molecular Biology;2024-10

5. Perspective Chapter: Targeting the Myeloid Compartment – Innovative Immunotherapy Strategies for Malignant Brain Tumors;Advanced Concepts and Strategies in Central Nervous System Tumors [Working Title];2024-09-13